15373-23-6

Basic information

• Product Name: (2R,3R,4R,5R)-2-((benzoyloxy)methyl)-5-(2,6-dichloro-9H-purin-9-yl)tetrahydrofuran-3,4-diyl dibenzoate
• Synonyms: (2R,3R,4R,5R)-2-((benzoyloxy)methyl)-5-(2,6-dichloro-9H-purin-9-yl)tetrahydrofuran-3,4-diyl dibenzoate
• CAS NO: 15373-23-6
• Molecular Weight: 633.444
• Mol File: 15373-23-6.mol
• Article Data: 14

Chemical Properties

• CAS DataBase Reference: (2R,3R,4R,5R)-2-((benzoyloxy)methyl)-5-(2,6-dichloro-9H-purin-9-yl)tetrahydrofuran-3,4-diyl dibenzoate(CAS DataBase Reference)
• NIST Chemistry Reference: (2R,3R,4R,5R)-2-((benzoyloxy)methyl)-5-(2,6-dichloro-9H-purin-9-yl)tetrahydrofuran-3,4-diyl dibenzoate(15373-23-6)
• EPA Substance Registry System: (2R,3R,4R,5R)-2-((benzoyloxy)methyl)-5-(2,6-dichloro-9H-purin-9-yl)tetrahydrofuran-3,4-diyl dibenzoate(15373-23-6)

Safety Data

• Hazardous Substances Data: 15373-23-6(Hazardous Substances Data)

Upstream product

• 918800-27-8 p-tolyl 2,3,5-tri-O-benzoyl-1-thio-β-D-ribofuranoside 
• 5451-40-1 2,6 dichloropurine 
• 69-89-6 xanthine 
• 6974-32-9 1-O-acetyl-2,3,5-tri-O-benzoyl-β-D-ribofuranose 
• 171887-02-8 2-amino-5-{[(dimethylamino)methylene]amino}-4,6-dichloropyrimidine 
• 55057-34-6 2,3,5-tri-O-acetyl-α-D-ribofuranosyl bromide 
• 39925-22-9 2,3,5-Tris-O-acetyl-β-D-ribofuranosyl bromide 
• 14215-97-5 1-O-acetyl-2,3,5-tri-O-benzoyl-D-ribofuranose 
• 5991-01-5 2,3,5-(tri-O-benzoyl)-D-ribofuranosyl chloride 

Downstream Products

• 167298-18-2 2-Chloro-N-(2,2-diphenylethyl)-adenosine 2',3',5'-tribenzoate 
• 442516-98-5 2-chloro-6-phenyl-9-(2,3,5-tri-O-benzoyl-β-D-ribofuranosyl)purine 
• 162684-68-6 2',3',5'-Tri-O-benzoyl-2-chloro-N-[(R)-1-(thiazolyl)thio-2-propyl]adenosine 
• 23541-34-6 2-chloro-N⁶-(2-methoxy-benzyl)-adenosine 
• 155769-07-6 2-methoxy-N-[(R)-1-phenoxy-2-propyl]adenosine 
• 13276-52-3 2,6-dichloropurine riboside 
• 163042-96-4 1-[2-chloro-6-[[(3-iodophenyl)methyl]amino]-9H-purin-9-yl]-1-deoxy-N-methyl-β-D-ribofuranuronamide 
• 1000980-71-1 ((3aR,4R,6R,6aR)-6-(2-chloro-6-(3-iodobenzylamino)9H-purine-9-yl) 2,2-dimethyl-tetrahydrofuro[3,4-d][1,3]dioxol-4-yl)methanol 
• 163152-31-6 MRS 542 
• 163152-42-9 2-chloro-N⁶-(3-iodobenzyl)-9-(2,3,5-tri-O-benzoyl-β-D-ribofuranosyl)adenine 
• 901776-34-9 (2R,3R_.4S,5R)-2-(6-(2-(biphenyl-4-yl)ethylamino)-2-chloro-9H-purin-9-yl)-5-(hydroxymethyl)-tetrahydrofuran-3,4-diol 
• 155769-05-4 2-chloro-N-[2-(phenylmethoxy)ethyl]adenosine 
• 162684-35-7 NNC 21-0136 
• 154493-11-5 2',3',5'-Tri-O-benzoyl-2-chloro-N-(phenylmethoxy) adenosine 

Relevant articles and documents

Development of a Novel and Scalable Process for the Synthesis of a Key Cangrelor Intermediate

-

A One-Pot Synthesis of Highly Functionalized Purines

Highly substituted purines were synthesized in good to high yields through a one-pot straightforward metal-free scalable method, using the Traube synthesis adapted to Vilsmeier-type reagents. From 5-amino-4-chloropyrimidines, new 9-aryl-substituted chloropurines and intermediates for peptide nucleic acid synthesis were prepared. Variant procedures allowing a rapid synthesis of ribonucleosides and 7-benzylpurine from 5-amidino-6-aminopyrimidines are also reported to illustrate the high potential of this versatile toolbox. This route appears to be particularly interesting in the field of nucleic acids for a direct and rapid access to various new 8-alkylpurine nucleosides.

Novel Adenine Derivatives and the Use Thereof

The present invention relates to a novel adenine derivative and a pharmaceutical use thereof and, more specifically, to a novel adenine derivative having a structure of chemical formula 1 or a pharmaceutically acceptable salt thereof, and to a composition containing the same for preventing or treating degenerative brain disease. The novel adenine derivative and the pharmaceutically acceptable salt thereof according to the present invention are adenosine A3 receptor agonists, and have an action of inhibiting the migration (or infiltration) of inflammatory cells (microglia, macrophages, neutrophils, etc.), to disease areas and the activities thereof. In addition, the adenine derivative according to the present invention was verified to suppress and treat brain injury more remarkably when compared with the known adenosine A3 receptor agonists in a cerebral ischemia experimental model, exhibit a significant effect by drug administration 10 hours after cerebral infarction, and allow long-term survival in spite of brain injury due to cerebral ischemia, and thus can be useful as an agent for treating and preventing degenerative brain disease including stroke.(AA,BB,CC,DD) Chemical formula 5COPYRIGHT KIPO 2015